恒瑞医药：子公司获得《药物临床试验批准通知书》

Core Viewpoint - Heng Rui Medicine announced the approval of clinical trial notifications for SHR-A2102 and Adalimumab injection by the National Medical Products Administration, indicating a significant step in the development of new drugs [2] Group 1 - The company’s subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., along with Shanghai Heng Rui Medicine Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., received the approval [2] - The clinical trials for the new drugs will commence shortly, reflecting the company's ongoing commitment to expanding its product pipeline [2]